Genetic polymorphisms of PDGFR/VEGFR2/VEGFR3/RET and their relevance to thrombocytopenia in mRCC patients treated with sunitinib

Trial Profile

Genetic polymorphisms of PDGFR/VEGFR2/VEGFR3/RET and their relevance to thrombocytopenia in mRCC patients treated with sunitinib

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 18 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top